文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

T细胞恶性肿瘤的过继性细胞疗法

Adoptive Cell Therapy for T-Cell Malignancies.

作者信息

Fang Karen Kai-Lin, Lee Jong Bok, Zhang Li

机构信息

Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, Canada.

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.

出版信息

Cancers (Basel). 2022 Dec 23;15(1):94. doi: 10.3390/cancers15010094.


DOI:10.3390/cancers15010094
PMID:36612092
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9817702/
Abstract

T-cell malignancies are often aggressive and associated with poor prognoses. Adoptive cell therapy has recently shown promise as a new line of therapy for patients with hematological malignancies. However, there are currently challenges in applying adoptive cell therapy to T-cell malignancies. Various approaches have been examined in preclinical and clinical studies to overcome these obstacles. This review aims to provide an overview of the recent progress on adoptive cell therapy for T-cell malignancies. The benefits and drawbacks of different types of adoptive cell therapy are discussed. The potential advantages and current applications of innate immune cell-based adoptive cell therapy for T cell malignancies are emphasized.

摘要

T细胞恶性肿瘤通常具有侵袭性,且预后较差。过继性细胞疗法最近已显示出有望成为血液系统恶性肿瘤患者的一种新的治疗方法。然而,目前将过继性细胞疗法应用于T细胞恶性肿瘤存在挑战。在临床前和临床研究中已经研究了各种方法来克服这些障碍。本综述旨在概述T细胞恶性肿瘤过继性细胞疗法的最新进展。讨论了不同类型过继性细胞疗法的优缺点。强调了基于先天免疫细胞的过继性细胞疗法对T细胞恶性肿瘤的潜在优势和当前应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fa1/9817702/ef713213aa28/cancers-15-00094-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fa1/9817702/2eea1c0a5271/cancers-15-00094-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fa1/9817702/ef713213aa28/cancers-15-00094-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fa1/9817702/2eea1c0a5271/cancers-15-00094-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fa1/9817702/ef713213aa28/cancers-15-00094-g002.jpg

相似文献

[1]
Adoptive Cell Therapy for T-Cell Malignancies.

Cancers (Basel). 2022-12-23

[2]
Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.

J Immunol Res. 2017-1-2

[3]
Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.

Immunotherapy. 2020-12

[4]
NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles.

Semin Hematol. 2020-10

[5]
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies.

Oncotarget. 2016-8-30

[6]
CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges.

Int Immunopharmacol. 2022-9

[7]
Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy.

Trends Pharmacol Sci. 2021-1

[8]
CAR-NK Cells: From Natural Basis to Design for Kill.

Front Immunol. 2021

[9]
CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.

Clin Pharmacol Ther. 2019-11-25

[10]
Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.

Oncoimmunology. 2020-6-10

引用本文的文献

[1]
Case report of non-gene editing CD7 CAR T cell therapy in CD7 Sézary syndrome: preclinical validation and first-in-human use.

Front Immunol. 2025-8-1

[2]
Advances and challenges in cancer immunotherapy: mechanisms, clinical applications, and future directions.

Front Pharmacol. 2025-6-13

[3]
Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients.

Drug Saf. 2025-3-19

[4]
The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.

Korean J Clin Oncol. 2024-12

[5]
Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells.

J Immunother Cancer. 2023-9

本文引用的文献

[1]
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.

Lancet Haematol. 2022-11

[2]
Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells.

Front Immunol. 2022

[3]
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.

Mol Ther. 2023-1-4

[4]
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.

Front Immunol. 2022

[5]
A Simple and Robust Single-Step Method for CAR-Vδ1 γδT Cell Expansion and Transduction for Cancer Immunotherapy.

Front Immunol. 2022

[6]
Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.

Front Oncol. 2022-5-6

[7]
Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial.

Blood. 2022-7-28

[8]
Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities.

Sci Immunol. 2022-4-22

[9]
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.

Clin Cancer Res. 2022-7-1

[10]
TCRαβ+ CD4-/CD8- "double negative" T cells in health and disease-implications for the kidney.

Kidney Int. 2022-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索